Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab (QL1706) Combined With Lenvatinib as Neoadjuvant Therapy in Renal Cancer
NCT07389629Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in clear cell renal cell carcinoma (ccRCC), sponsored by Sun Yat-sen University. Started Nov 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07389629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389629.